Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
99 hedge funds and large institutions have $186M invested in Esperion Therapeutics in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 18 closing their positions.
352% more call options, than puts
Call options by funds: $2.99M | Put options by funds: $661K
65.72% more ownership
Funds ownership: 0% → 65.72% (+66%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
3% less funds holding
Funds holding: 102 → 99 (-3)
7% less capital invested
Capital invested by funds: $200M → $186M (-$14.1M)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
+$4.33M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.64M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$3.48M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$2.61M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$9.55M |
| 2 |
Renaissance Technologies
New York
|
-$4.42M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$2.44M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.77M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.04M |
ESPR Hedge Fund Activity: Q4 2016 in Review
99 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2016, worth a combined $186M — down 7% from $200M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ESPR and 15 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 29 added.
The largest buyer was Senzar Asset Management, opening a new position worth an estimated $4.33M. The largest seller was VOYA Investment Management, exiting entirely with an estimated $9.55M sold.
- 99 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2016, down from 102 in Q3 2016.
- Funds reported $186M of Esperion Therapeutics stock for Q4 2016, down 7% quarter-over-quarter.
- 15 funds opened new Esperion Therapeutics positions in Q4 2016 and 18 closed out, a net change of -3 holders.
- The largest Esperion Therapeutics buyer in Q4 2016 was Senzar Asset Management, an estimated $4.33M added.
- The largest Esperion Therapeutics seller in Q4 2016 was VOYA Investment Management, an estimated $9.55M sold.
Based on aggregated 13F filings for Q4 2016.